RIGL RIGEL PHARMACEUTICALS INC
Price Chart
Executive Summary
Rigel Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.44, missing consensus of $0.74 by 40.5%, despite 10% YoY revenue growth to $58.8M. Net income declined 24% YoY to $8.7M, and the company maintained its full-year revenue guidance of $275-290M. The miss was driven by higher R&D and SG&A costs, overshadowing strong product sales growth.
Key Financial Metrics
Actionable Insight
The 40% EPS miss signals deteriorating profitability despite revenue growth. Watch for analyst downgrades and potential cost-cutting measures. The reaffirmed guidance provides a floor, but the collaboration termination adds pipeline uncertainty. Monitor next quarter's margins and any updates on the R289 Phase 1b study.
Key Facts
- Q1 2026 total revenues: $58.8M (up 10% YoY from $53.3M)
- Net product sales: $54.9M (up 26% YoY)
- GAAP diluted EPS: $0.44 vs consensus $0.74 (40.5% miss)
- Net income: $8.7M vs $11.4M in Q1 2025 (down 24%)
- 2026 revenue guidance reaffirmed at $275-290M
- Eli Lilly terminated collaboration on ocadusertib (effective June 15, 2026)
- Debt restructured: repaid $40M term loan, drew $8M on new $40M revolver
- Cash, cash equivalents and short-term investments: $146.7M as of March 31, 2026
Financial Impact
EPS miss of $0.30 vs consensus; net income decline of $2.8M YoY
Risk Factors
- Eli Lilly collaboration termination may impact future royalty streams
- Rising R&D and SG&A expenses pressuring margins
- High dependence on TAVALISSE sales (68% of product revenue)
- Potential need for additional capital if profitability continues to decline
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001034842-26-000033 |
| Document: 0001034842-26-000033-index.html | 0001034842-26-000033 |
| Document: 0001034842-26-000033.txt | 0001034842-26-000033 |
| 8-K Data (Synthetic) | 0001034842-26-000033 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 20, 2026
today
|
8-K
| $28.82 awaiting T+5 | awaiting T+5 | — | $28.82 (−0.00%) |
|
May 12, 2026
8d ago
|
8-K
| $32.13 $28.30 | ▼ −11.92% | ▼ −10.76% | $28.82 (−10.30%) |
|
May 5, 2026
15d ago
|
8-K
| $26.67 $29.37 | ▼ −10.12% | ▼ −8.99% | $28.82 (−8.06%) |
|
Apr 21, 2026
29d ago
|
8-K
| $30.47 $29.16 | ▲ +4.30% | ▲ +4.35% | $28.82 (+5.42%) |
|
Apr 3, 2026
6w ago
|
DEFA14A
| $27.36 $29.97 | ▲ +9.54% | ▲ +5.40% | $28.82 (+5.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access